3003864-86-3
Chemical Structure
VV261
- CAS No.: 3003864-86-3
- Formula:C28H34FN3O11
- Molecular Weight:607.58
InChIKey: NQRKQWPVFDFSBT-BUUPBASBSA-N
SMILES: O=C(C1=CC=CN=C1)OCN2C(N(C=CC2=O)[C@@H]3O[C@@](COC(C(C)C)=O)(F)[C@@H](OC(C(C)C)=O)[C@H]3OC(C(C)C)=O)=O
Biological Activity: VV261 is an orally active prodrug of 4'-fluorouridine. VV261 inhibits viral RNA-dependent RNA polymerase. VV261 exhibits antiviral activity against CCHFV, SFTSV and LCMV. VV261 can be used in research related to viral infections[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
VV261 | 99.92% | VV261 is an orally active prodrug of 4'-fluorouridine. VV261 inhibits viral RNA-dependent RNA polymerase. VV261 exhibits antiviral activity against CCHFV, SFTSV and LCMV. VV261 can be used in research related to viral infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Wang X, et al. Oral VV261 administration protects mice from lethal Crimean-Congo hemorrhagic fever virus challenge. J Virol. 2025 Dec 23;99(12):e0158325. [Content Brief]
- [2]. Cheng Y, et al. Design and Development of a Novel Oral 4'-Fluorouridine Double Prodrug VV261 against SFTSV. J Med Chem. 2025;68(9):9811-9826. [Content Brief]
Keywords